PLGA-Based Drug Delivery Systems: A Promising Carrier for Antidiabetic Drug Delivery

Poly(lactic-co-glycolic acid) (PLGA) nanoparticles have emerged as a versatile platform for drug delivery due to their biodegradability, biocompatibility, and tunable release kinetics. One of the primary applications of PLGA nanoparticles in diabetes management is the encapsulation and controlled release of insulin, overcoming the limitations of frequent injections. Such systems provide sustained and stable glycemic control, reducing the risk of hypoglycemia. Different types of PLGAs and their derivatives are used for preparing varieties of micro/nanocarriers to deliver insulin as well as diverse antidiabetic molecules, including glucagon-like peptide-1 (GLP-1) and its analog (exendin-4), crocetin, metformin hydrochloride, gliclazide, ferulic acid (FA), etc., to reduce hyperglycemia. Here the current state of research and development in PLGA-based drug delivery systems for diabetes management are summarized. Various strategies employed to enhance the targeting specificity of PLGA nanoparticles in diabetes therapy are explored. The outcome will provide an insight into the drug delivery potential and efficiency of PLGA in managing hyperglycemia and that will be useful in designing novel therapeutic to improve better control of diabetes mellitus. As research in this field continues to progress, PLGA-based systems hold great potential for revolutionizing the treatment paradigm for diabetes mellitus. This review outlines current evidence on Poly (lactic-co-glycolic acid) (PLGA) benefits in managing postprandial glycemia. It highlights PLGA-based micro/nano-carriers for delivering anti-diabetic molecules such as insulin, GLP-1, Exendin-4, Crocetin, Metformin hydrochloride, Gliclazide, Ferulic acid (FA), etc. via orally and subcutaneously to reduce hyperglycemia. The findings enhance understanding of PLGA's prophylactic role and its formulations in diabetes mellitus management. image